Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6

Molecular Carcinogenesis

Volumn 21, Issue 3, 1998, Pages 215-222

  Inoue, Tadao ^a   Oka, Kiyomasa ^a   Yong Il, Hwang ^a   Vousden, Karen H ^b   Kyo, Satoru ^a   Jing, Pan ^a   Hakura, Akira ^a   Yutsudo, Masuo ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Human papillomavirus 16; Mutant E6 genes; p53 degradation; Tumorigenicity

Indexed keywords

PROTEIN P53;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL TRANSFORMATION; HUMAN; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CULTURE MEDIA, SERUM-FREE; GENE EXPRESSION; GENES, VIRAL; GENETIC VECTORS; HUMANS; MICE; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TRANSFORMATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE; ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MURINAE; PAPILLOMAVIRUS; PAPOVAVIRIDAE;

EID: 0031969677     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199803)21:3<215::AID-MC9>3.0.CO;2-K     Document Type: Article

References (47)

1. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184:9-13, 1991.
2. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314:111-114, 1985.
3. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell line. J Virol 61:962-971, 1987.
4. Kanda T, Watanabe S, Yoshiike K. Immortalization of primary rat cells by human papillomavirus type 16 subgenomic DNA fragments controlled by the SV40 promoter. Virology 165:321-325, 1988.
5. Watanabe S, Kanda T, Yoshiike K. Human papillomavirus type 16 transformation of primary human embryonic fibroblasts requires expression of open reading frame E6 and E7. J Virol 63:965-969, 1989.
6. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV 16 E6 and E7 proteins cooperate to immortalize primary human foreskin keratinocytes. EMBO J 8:3905-3910, 1989.
7. Kanda T, Furuno A, Yoshiike K. Human papillomavirus type 16 open reading frame E7 encodes a transforming gene for rat 3Y1 cells. J Virol 62:610-613, 1988.
8. Yutsudo M, Okamoto Y, Hakura A. Functional dissociation of transforming genes of human papillomavirus type 16. Virology 166:594-597, 1988.
9. Kitasato H, Hillova J, Lenormand M, Hill M. Tumorigenicity of the E6 and E6-E7 gene constructions derived from human papillomavirus type 33. Anticancer Res 11:1165-1172, 1991.
10. Inoue T, Kyo S, Kiyono T, et al. Correlation between tumorigenicity and expression levels or splicing patterns of transcripts of the human papillomavirus type 16 E6 gene. Jpn J Cancer Res 85:357-363, 1994.
11. von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 48:3780-3786, 1988.
12. Steele C, Sacks PG, Adler-Storthz K, Shillitoe EJ. Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. Cancer Res 52:4706-4711, 1992.
13. Barbosa MS, Lowy DR, Schiller J. Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol 63:1404-1407, 1989.
14. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937, 1989.
15. Phelps WC, Yee CL, Munger K, Howley PM. The human papillomavirus type 16 E7 gene encodes transactivation and transformation similar to those of adenovirus E1a. Cell 53:539-547, 1988.
16. Melillo RM, Helin K, Lowy DR, Schiller JT. Positive and negative regulation of cell proliferation by E2F-1: Influence of protein level and human papillomavirus oncoproteins. Mol Cell Biol 14:8241-8249, 1994.
17. Edomonds C, Vousden KH. A point mutational analysis of human papillomavirus type 16 E7 protein. J Virol 63:2650-2656, 1989.
18. Takami Y, Sasagawa T, Sudiro TM, Yutsudo M, Hakura A. Determination of the functional difference between human papillomavirus type 6 and 16 E7 proteins by their 30 N-terminal amino acid residues. Virology 186:489-495, 1992.
19. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci USA 89:4442-4446, 1992.
20. Sang BC, Barbosa MS. Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc Natl Acad Sci USA 89:8063-8067, 1992.
21. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68:4262-4273, 1994.
22. Liang XH, Volkmann M, Klein R, Herman B, Lockett SJ. Colocalization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene 8:2645-2652, 1993.
23. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 248:76-79, 1990.
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell 63:1129-1136, 1990.
25. Desaintes C, Hallez S, Alphen PV, Burny A. Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type V6. J Virol 66:325-333, 1992.
26. Etscheid BG, Foster SA, Galloway DA. The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein p53. Virology 205:583-585, 1994.
27. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE. Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci USA 89:9210-9214, 1992.
28. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763-8767, 1989.
29. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989.
30. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6:873-875, 1991.
31. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88:5523-5527, 1991.
32. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 5323-5328, 1992.
33. Choo KB, Chong KY. Absence of mutation in the p53 and retinoblastoma susceptibility genes in primary cervical carcinomas. Virology 193:1042-1046, 1993.
34. Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koeffler HP. p53 mutations in HPV-negative cervical carcinoma. Oncogene 9:205-210, 1994.
35. Cepko CL, Roberts BE, Mulligan RC. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 37:1053-1062, 1984.
36. Mann R, Mulligan RC, Baltimore C. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 33:153-159, 1983.
37. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556, 1991.
38. Chen C, Okayama H. High efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752, 1987.
39. Maniatis T, Fritsch EF, Sambrook J. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989.
40. Schneider-Gadicke A, Schwarz E. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J 5:2285-2292, 1986.
41. Sedman SA, Barbosa MS, Vass WC, et al. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 65:4860-4866, 1991.
42. 1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents. Oncogene 13:625-632, 1996.
43. Foster SA, Demers GW, Etscheid BG, Galloway DA. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68:5698-5705, 1994.
44. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 11:3045-3052, 1992.
45. Crook T, Fisher C, Masterson PJ, Vousden KH. Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 9:1225-1230, 1994.
46. Pim D, Storey A, Thomas M, Massimi P, Banks L. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalization of primary BMK cells. Oncogene 9:1869-1876, 1994.
47. Thomas M, Massimi P, Jerkins J, Banks L. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene 10:261-268, 1995.